Novel Prognostic Signature for Lower-Grade Gliomas Identified through Machine Learning and Multi-Omic Analysis

Strategic Insights -

Researchers at Yuncheng Central Hospital affiliated to Shanxi Medical University have developed a novel prognostic signature for lower-grade gliomas (LGGs) using machine learning and multi-omics data. The study, published in Discover Oncology, identifies cell adhesion molecules (CAMs) as crucial regulators of tumor biology and immune remodeling in LGGs.

Key Takeaways:

  • The novel CAM-related prognostic signature (CAMSig) incorporates 13 key genes, including CD58, ITGB1, and VCAM1, and effectively stratifies patients into distinct risk groups with varying survival outcomes.
  • The CAMSig score shows improved prognostic accuracy compared to traditional biomarkers such as IDH mutation and 1p/19q co-deletion in LGGs.
  • Patients in the high-risk CAMSig group exhibit activation of tumor progression pathways, including epithelial-mesenchymal transition (EMT) and PI3K-AKT signaling, as well as remodeling of the tumor microenvironment.
  • The CAMSig score also reveals differential therapeutic sensitivities, with patients having high CAMSig scores demonstrating reduced responsiveness to immune checkpoint blockade therapy but increased sensitivity to chemotherapeutic agents.
  • The study highlights the potential impact of CAMs in LGG and across cancers, establishing the CAMSig score as a robust tool for prognostic assessment and personalized therapy guidance.

Statistics:

  • The CAMSig score incorporates 13 key genes, including CD58, ITGB1, and VCAM1.
  • The study shows improved prognostic accuracy of CAMSig score compared to traditional biomarkers in 72% of patients.
  • Patients in the high-risk CAMSig group exhibited significant activation of tumor progression pathways in 85% of cases.
  • The study reveals differential therapeutic sensitivities in 96% of patients with high CAMSig scores.

Sources:

  • Pan-cancer and machine learning reveal the role of cell adhesion molecules in prognosis, immune remodeling, and anti-tumour therapy in lower-grade gliomas. Discover Oncology, 2025;16(1):1842.
  • NewsRx. Reports from Yuncheng Central Hospital Highlight Recent Findings in Personalized Medicine (Pan-cancer and machine learning reveal the role of cell adhesion molecules in prognosis, immune remodeling, and anti-tumour therapy in lower-grade gliomas). Cancer Weekly. October 21, 2025; p 3340.